Cure NF with Jack: One Family’s Impact on Rare Disease Research

The Science of Healthier Models in Animal Welfare Research

Can Powerful New Tools Reduce Animal Testing? VCG: The Virtual Animal

Can Psychedelics Reset the Brain?

Reading the EU Roadmap

Advancing Oncology Through Open Science

The YWHAG Ultra-Rare Mutation: A Family Hunts for Solutions

Laboratory Biosecurity for Exotic Viruses

From Cell Painting to Toxicology: Advancing Treatment for PACS2 Therapy

Hold Your Fire: A New Weapon Against Autoimmune Diseases

A New Era for FOXG1: The Race to First‑in‑Human Trials

Why you should consider outsourcing your research facility support

A Dean’s advice for looking for vivarium operation partners

Top considerations when selecting an outsourced vivarium staffing partner

A Dean’s reflection after outsourcing staff support

How to leverage outsourced staff to reach your research program goals

How outsourcing can help you overcome vivarium challenges

CEO Jim Foster Reflects on his Remarkable 50 years at Charles River

Dose of Science 2025: That’s a Wrap

Employees Find Belonging at Charles River

Bioanalytical Innovation Driving Efficiency, Preserving Quality

Discovery-to-Clinic Bioanalysis Faster Assay Development Through Continuity

Successful Bioanalytical Partnership

Charles River and Foster Love in Action

Ab Development to IND: Early Risk Mitigation, Target Specificity, & mRNA-LNP Delivery

Quality Culture in CGT: Megha Sharma on Patient Safety

Celsis® Rapid Detection – Objective sterility results in 6 days, built for real-world QC

Transforming Targets Into Candidates Logica®

Research Animals: Handle With Care

Biologics Testing Expertise: Werner Schick on GMP & Compliance

Viral Vector Success: Beth Tebeau on On-Time Manufacturing

Biologics Testing Confidence: David Russell on Speed & Precision

Lean CDMO Operations: Kerstin Dolph on Quality & Partnership

Agile CDMO Excellence: Ahmad Hussin on Client-Centric Solutions

Interview with Denise Teber and Carolin Justenhoven | 2025 Viral Safety & Viral Clearance Summit

Defining Critical Quality Attributes in Cell & Gene Therapy | CGT Summit 2025

Commercializing Mutation-Agnostic Gene Therapy | Samarendra Mohanty Interview

Global Launch Strategies & Patient Partnerships in CGT | Rita Johnson-Greene

End-to-End CDMO Solutions for CGT Innovation | Ramin Baghirzade Interview

Precision Medicine & Rare Disease Strategy | Nasha Fitter at CGT Summit 2025

Patient-Led Gene Therapy for SLC13A5 Epilepsy | TESS Foundation Story

Startup Spotlight: NVI Therapeutics’ Non-Viral CAR-T Platform | CGT Summit 2025

CGT Startup Showcase: Emerging Therapies & Platforms

Investor Perspectives on CGT Innovation & Commercial Strategy

CAR-T Therapy Development: Manufacturing, Strategy & Scale

Viral Vector Gene Therapy: From Discovery to Commercialization

FOXG1 Syndrome: A Parent-Led Path to Gene Therapy

NASA’s Genomic Research on Space Radiation & Human Health

FDA’s 2024 Vision for Cell & Gene Therapy Innovation

AAV Gene Therapy: From Discovery to Commercialization | CGT Summit 2023

Advancing CAR-T Therapy: Manufacturing, Analytics & Allogeneic Platforms

Future of Viral Vector Manufacturing: Plasmid Innovation & Regulatory Trends

Commercializing Cell Therapies: CDMO Partnerships & GMP Readiness | CGT Summit 2023

Quality Control in Cell & Gene Therapy: Defining CQAs & Regulatory Strategy

Accelerating Gene Therapy Development: CDMO Solutions from Charles River

Navigating Global Cell & Gene Therapy Regulations: EU vs US | CGT Summit 2023

Gene Therapy for Hemophilia: AAV Advances & Clinical Impact | CGT Summit 2023

Plasmid DNA in Gene Therapy, mRNA & Vaccines: Manufacturing & Regulatory Insights

Patient-Led Gene Therapy for SPG15: The Maddi Foundation Story | CGT Summit 2023

Gene Therapy Funding & Market Trends: Investor Insights from CGT Summit 2023